Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 135.78B -57.0% |
| Revenue (ttm) | 41.38B +6.4% |
| Net Income | 13.72B +1.4% |
| EPS | 3.08 +1.8% |
| Shares Out | n/a |
| PE Ratio | 9.90 |
| Forward PE | 10.91 |
| Dividend | 1.57 (5.14%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 215,068 |
| Average Volume | 329,873 |
| Open | 31.18 |
| Previous Close | 30.86 |
| Day's Range | 30.24 - 31.21 |
| 52-Week Range | 30.24 - 71.53 |
| Beta | 0.27 |
| RSI | 28.83 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk: A Strong Contender in the Pharmaceutical Arena
Explore the exciting world of Novo Nordisk (NVO 1.07%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market tre...
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?
One of these companies' lineup and pipeline within weight management and outside look much stronger. Valuation does not tip the scale in the other's favor.
Novo Nordisk Wins FDA Nod For Awiqli, First Once-Weekly Basal Insulin
(RTTNews) - Novo Nordisk A/S (NVO) yesterday announced that the U.S. FDA has approved Awiqli (insulin icodec-abae), the first and only once-weekly basal insulin for adults with type 2 diabetes. The ap...
Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market
Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. NVO is expanding manufacturing, advancing next-generation therapies like CagriSema, and leveraging p...
Articles of Association for Novo Nordisk A/S 2026
500 - Internal server error. Server Error 500 - Internal server error.
Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 Medications, Including Wegovy Pill
(RTTNews) - Hims & Hers Health Inc. (HIMS) announced that a wide range of Novo Nordisk's FDA-approved GLP-1 medications are now available to eligible customers. This includes the Wegovy pill, the only...
US FDA approves Novo's insulin injection for type 2 diabetes
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk 's insulin injection, Awiqli, to improve blood sugar levels in adults living with type 2 diabetes, the company said ...
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..
Novo Nordisk A/S (NOVO:CA) Shareholder/Analyst Call Transcript
Novo Nordisk A/S (NOVO:CA) Shareholder/Analyst Call Transcript
Mars CEO joins board of Ozempic-maker Novo Nordisk
Novo Nordisk has appointed Poul Weihrauch, CEO of US food giant Mars, as board observer as the Danish drugmaker seeks to strengthen its position in the highly competitive US obesity market.
What's Happening With Novo Nordisk Stock Today?
Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including th...
Novo Nordisk Falls 45% as Investors Question Strategy at AGM
Novo Nordisk Falls 45% as Investors Question Strategy at AGM
Novo Nordisk (NVO) Expands Access to FDA-Approved Weight Loss Medications
Novo Nordisk (NVO) Expands Access to FDA-Approved Weight Loss Medications
Novo Nordisk (NVO) Gains Approval for Share Buyback and Board Re-election
Novo Nordisk (NVO) Gains Approval for Share Buyback and Board Re-election
Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers
Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill Hims & Hers Health, Inc. (NYSE: HIMS) today announced tha...
The market for weight loss drugs is exploding and patients may have several new options in coming years—here's a look, in charts
The market for weight loss drugs is exploding and patients may have several new options in coming years.
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Lars Rebien Sørensen, chair of the Board of Directors, stated: “2025 was a ye...
Novo Nordisk appoints Mars CEO as board observer
Novo Nordisk on Thursday elected Poul Weihrauch, CEO of family-owned U.S. candy and pet food giant Mars, as observer to its board, as the drugmaker seeks to strengthen its position in the highly co...
As patents on weight-loss drugs expire, doctors and patients hotly anticipate cheaper generics
Now that patents have expired, generic versions of Novo Nordisk's blockbuster weight-loss drugs could arrive in Canada within months, according to experts. Doctors say these cheaper versions will impr...
China’s weight-loss drug makers take on global giants as Novo Nordisk patent expires
At least 10 weight-loss injections and oral pills are lining up for regulatory approval in China, in a market projected to reach about US$14 billion by 2030. Novo Nordisk’s blockbuster semaglutide, wh...
Novo Nordisk cuts Wegovy price in South Africa for a second time
Novo Nordisk is cutting South African prices of its weight-loss drug Wegovy for a second time since it launched in August, local executives said on Wednesday, pointing to fierce competition in a mark...
Triple-G Agonist UBT251 Lowers HbA1c By Up To 2.16% In Chinese Phase 2 Diabetes Trial
(RTTNews) - The United Laboratories International Holdings Ltd. (TUL) and Novo Nordisk A/S (NVO) have announced promising topline results from a phase 2 trial of investigational drug UBT251 in Chinese...
Novo Nordisk Says Experimental Diabetes and Obesity Drug Shows Positive Results
The drugmaker said UBT251 achieved mean body weight reduction of up to 9.8% after a 24-week trial.
Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer
Regulators recently approved Wegovy HD, which is a higher-dose version of its popular weight loss drug. Wegovy HD helped people lose 20.7%, on average, in a clinical trial.
Novo Nordisk: Priced For Disaster
Novo Nordisk shares have slumped despite a promising partnership with Hims & Hers Health to distribute semaglutide drugs via telehealth platform. The agreement grants HIMS access to FDA-approved Ozemp...